These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8819514)

  • 41. Assessment of dependence potential and abuse liability of Δ
    Vanegas SO; Reck AM; Rodriguez CE; Marusich JA; Yassin O; Sotzing G; Wiley JL; Kinsey SG
    Drug Alcohol Depend; 2022 Nov; 240():109640. PubMed ID: 36179506
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cannabinoid-Induced Conditioned Place Preference, Intravenous Self-Administration, and Behavioral Stimulation Influenced by Ghrelin Receptor Antagonism in Rats.
    Charalambous C; Havlickova T; Lapka M; Puskina N; Šlamberová R; Kuchar M; Sustkova-Fiserova M
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673659
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Druggable Targets in Endocannabinoid Signaling.
    Gregus AM; Buczynski MW
    Adv Exp Med Biol; 2020; 1274():177-201. PubMed ID: 32894511
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse effects of heavy cannabis use: even plants can harm the brain.
    Sideli L; Trotta G; Spinazzola E; La Cascia C; Di Forti M
    Pain; 2021 Jul; 162(Suppl 1):S97-S104. PubMed ID: 32804835
    [No Abstract]   [Full Text] [Related]  

  • 45. Association between cannabis and the eyelids: A comprehensive review.
    Nguyen AX; Wu AY
    Clin Exp Ophthalmol; 2020 Mar; 48(2):230-239. PubMed ID: 31747112
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tolerance and dependence to Δ9-tetrahydrocannabinol in rhesus monkeys: Activity assessments.
    Wilkerson JL; Schulze DR; McMahon LR
    PLoS One; 2019; 14(3):e0209947. PubMed ID: 30861005
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.
    Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE
    Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders.
    Suryadevara U; Bruijnzeel DM; Nuthi M; Jagnarine DA; Tandon R; Bruijnzeel AW
    Curr Neuropharmacol; 2017; 15(6):800-814. PubMed ID: 27804883
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chronic Δ9-Tetrahydrocannabinol during Adolescence Differentially Modulates Striatal CB1 Receptor Expression and the Acute and Chronic Effects on Learning in Adult Rats.
    Weed PF; Filipeanu CM; Ketchum MJ; Winsauer PJ
    J Pharmacol Exp Ther; 2016 Jan; 356(1):20-31. PubMed ID: 26462539
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of gonadal hormones on cannabinoid dependence.
    Marusich JA; Craft RM; Lefever TW; Wiley JL
    Exp Clin Psychopharmacol; 2015 Aug; 23(4):206-16. PubMed ID: 26237318
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hormonal status and age differentially affect tolerance to the disruptive effects of delta-9-tetrahydrocannabinol (Δ(9)-THC) on learning in female rats.
    Winsauer PJ; Filipeanu CM; Weed PF; Sutton JL
    Front Pharmacol; 2015; 6():133. PubMed ID: 26191005
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
    Deng L; Cornett BL; Mackie K; Hohmann AG
    Mol Pharmacol; 2015 Jul; 88(1):64-74. PubMed ID: 25904556
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cannabinoid abuse and addiction: Clinical and preclinical findings.
    Panlilio LV; Goldberg SR; Justinova Z
    Clin Pharmacol Ther; 2015 Jun; 97(6):616-27. PubMed ID: 25788435
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
    Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU
    Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
    Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG
    Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of sex differences in cannabinoid dependence.
    Marusich JA; Lefever TW; Antonazzo KR; Craft RM; Wiley JL
    Drug Alcohol Depend; 2014 Apr; 137():20-8. PubMed ID: 24582909
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tales from the dark side: do neuromodulators of drug withdrawal require changes in endocannabinoid tone?
    Oleson EB; Cachope R; Fitoussi A; Cheer JF
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jul; 52():17-23. PubMed ID: 23911441
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Marijuana dependence: not just smoke and mirrors.
    Ramesh D; Schlosburg JE; Wiebelhaus JM; Lichtman AH
    ILAR J; 2011; 52(3):295-308. PubMed ID: 23382144
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.
    Panlilio LV; Justinova Z; Goldberg SR
    Pharmacol Ther; 2013 Apr; 138(1):84-102. PubMed ID: 23333350
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats.
    Wright FL; Rodgers RJ
    Psychopharmacology (Berl); 2013 Mar; 226(2):415-31. PubMed ID: 23142959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.